Modelling of increased homocysteine in ischaemic stroke -: Post-hoc cross-sectional matched case-control analysis in young patients

被引:6
作者
Atanassova, Penka A.
Angelova, Evgeniya
Tzvetanov, Plamen
Semerdjieva, Maria
Dimitrov, Borislav D.
机构
[1] Med Univ, Dept Neurol, Plovdiv 4000, Bulgaria
[2] Med Univ, Dept Clin Lab, Plovdiv 4000, Bulgaria
[3] Med Univ, Dept Social Med & Hlth Management, Plovdiv 4000, Bulgaria
[4] Med Univ Hosp St George, Informat Serv Sect, Plovdiv 4000, Bulgaria
关键词
homocysteine; epidemiology; ischaemic stroke; young patient;
D O I
10.1590/S0004-282X2007000100007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background & Purpose: Hyperhomocysteinaemia has been postulated to participate in pathogenesis of ischaemic stroke (IS). However, especially in young adults, there is possibility of significantly increased IS risk due to increased 'normal' homocysteinaemia, i.e., 'hidden' ('pathologically dormant') prevalence within a healthy, normally-defined range. We performed a post-hoc modelling investigation on plasma total homocysteinaemia (THCY) in gender- and age-matched young patients in the acute IS phase. We evaluated relationships between THCY and prevalence of other potential risk factors in 41 patients vs. 41 healthy controls. Method: We used clinical methods, instrumental and neuroimmaging procedures, risk factors examination, total plasma homocysteine measurements and other laboratory and statistical modelling techniques. Results: IS patients and healthy controls were similar not only for matching variables, but also for smoking, main vitamin status, serum creatinine and lipid profile. Patients with IS, however, had lower vitamin 86 levels and higher THCY, fibrinogen and triglycerides (TGL). At multivariate stepwise logistic regression only increased THCY and TGL were significantly and independently associated with the risk for stroke (72% model accuracy, p(model)=0.001). An increase of THCY with 1.0 mu mol/L was associated with 22% higher risk of ischaemic stroke [adjusted OR=1.22 (95%Cl 1.03=1.44)]. In this way, novel lower cut-off value for HCY of 11.58 mu mol/L in younger patients has been revealed (ROCAUC=0.67, 95Cl% 0.55-0.78, p=0.009). Conclusion: The new THCY cut-off clearly discriminated between absence and presence of IS (sensitivity > 63%, specificity > 68%) irrespectively of age and gender and may be applied to better evaluate and more precisely define, as earlier as possible, the young patients at increased IS risk.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 42 条
[1]  
ANGELOVA EA, 2005, FOLIS MED, V477, P53
[2]  
ATANASSOVA PA, 2006, BULG NEUROL, V6, P17
[3]   A PROSPECTIVE-STUDY OF ACUTE CEREBROVASCULAR-DISEASE IN THE COMMUNITY - THE OXFORDSHIRE COMMUNITY STROKE PROJECT 1981-86 .2. INCIDENCE, CASE FATALITY RATES AND OVERALL OUTCOME AT ONE YEAR OF CEREBRAL INFARCTION, PRIMARY INTRACEREBRAL AND SUBARACHNOID HEMORRHAGE [J].
BAMFORD, J ;
SANDERCOCK, P ;
DENNIS, M ;
BURN, J ;
WARLOW, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (01) :16-22
[4]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[5]   Effects of coenzyme Q10 in early Parkinson disease -: Evidence of slowing of the functional decline [J].
Shults, CW ;
Oakes, D ;
Kieburtz, K ;
Beal, MF ;
Haas, R ;
Plumb, S ;
Juncos, BL ;
Nutt, J ;
Shoulson, I ;
Carter, J ;
Kompoliti, K ;
Perlmutter, JS ;
Reich, S ;
Stern, M ;
Watts, RL ;
Kurlan, R ;
Molho, E ;
Harrison, M ;
Lew, M .
ARCHIVES OF NEUROLOGY, 2002, 59 (10) :1541-1550
[6]  
Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5
[7]   Homocysteine, renal function, and risk of cardiovascular disease [J].
Clarke, R ;
Lewington, S ;
Landray, M .
KIDNEY INTERNATIONAL, 2003, 63 :S131-S133
[8]   Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022
[9]   Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis [J].
Danesh, J ;
Lewington, S ;
Thompson, SG ;
Lowe, GDO ;
Collins, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1799-1809
[10]   Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease [J].
De Bree, A ;
Verschuren, WMM ;
Kromhout, D ;
Kluijtmans, LAJ ;
Blom, HJ .
PHARMACOLOGICAL REVIEWS, 2002, 54 (04) :599-618